- $22.26bn
- $22.71bn
- $982.02m
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US Health Secretary Kennedy Jr. adds eight new members to key health committee (updated)
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Brief: Guardant Health To Appeal Federal District Court Judgment
U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute (updated)
U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute
Soccer-Sheffield United's ex-owners winds up company which bought club (updated)
U.S. RESEARCH ROUNDUP-Cloudflare, Replimune, Walmart
Guardant Health Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. RESEARCH ROUNDUP-Apple, Amazon, Mastercard
Brief: Guardant Health Inc Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing
Guardant Health Q2 revenue beats estimates, lifts 2026 outlook
Brief: Guardant Health Q2 Adjusted EPS USD -0.42 Vs. IBES Estimate USD -0.41
FDA approves Freenome's blood test for colorectal cancer screening (updated)
FDA approves Freenome's blood test for colorectal cancer screening
Brief: Zydus Lifesciences Signs MoU With Apollo Hospitals
Guardant Health rises on UnitedHealth coverage boost for colorectal cancer kit
U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle